Actively Recruiting
Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction
Led by Jinling Hospital, China · Updated on 2026-02-03
910
Participants Needed
1
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).
CONDITIONS
Official Title
Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with acute ischemic stroke
- Clinical symptoms consistent with perforating artery infarction with NIHSS score 5 or less and consciousness item 1a of 1 or less
- Time from stroke onset to randomization within 48 hours
- Diffusion-weighted imaging showing a single infarct in the perforating artery territory with maximum diameter 30 mm or less, meeting at least one of these: diameter 15 mm or less involving two or more axial slices; diameter greater than 15 mm; connected to ventral surface of pons but not crossing midline
- Stenosis of parent artery less than 70%
- Signed informed consent provided by patient or legally authorized representative
You will not qualify if you...
- Received intravenous thrombolysis or endovascular treatment before randomization
- Stroke caused by brain tumor, traumatic brain injury, hematologic disorders, or other secondary causes
- History of intracranial hemorrhage
- Contraindications to RIC such as severe upper limb soft tissue injury, fracture, subclavian artery stenosis, or peripheral vascular disease
- Uncontrolled severe hypertension with systolic BP 180 mmHg or higher or diastolic BP 110 mmHg or higher
- Severe liver or kidney dysfunction as indicated by specific laboratory values
- Thrombocytopenic purpura, coagulation disorders, or active visceral bleeding
- Acute fundus hemorrhage
- History of severe aphasia or psychiatric disorders affecting clinical assessment
- Life expectancy less than 90 days
- Pregnancy
- Inability to comply with follow-up
- Participation in other clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Jinling Hospital, Medical School of Nanjing University, Nanjing
Nanjing, Jiangsu, China, 210002
Actively Recruiting
Research Team
W
Wusheng Zhu, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here